Nazia Raja-Khan1, Julie Shah2, Christy M Stetter3, Mary E J Lott4, Allen R Kunselman3, William C Dodson5, Richard S Legro5. 1. Division of Endocrinology, Diabetes, and Metabolism, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Electronic address: nrajakhan@psu.edu. 2. Division of Endocrinology, Diabetes, and Metabolism, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. 3. Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. 4. Heart and Vascular Institute, Pennsylvania State University College of Medicine, Hershey, Pennsylvania. 5. Department of Obstetrics and Gynecology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Abstract
OBJECTIVE: To determine the effects of high-dose vitamin D on insulin sensitivity in polycystic ovary syndrome (PCOS). DESIGN: Randomized, placebo-controlled trial. SETTING: Academic medical center. PATIENT(S): Twenty-eight women with PCOS. INTERVENTION(S): Vitamin D3, 12,000 IU, or placebo daily for 12 weeks. MAIN OUTCOME MEASURE(S): The primary outcome was quantitative insulin sensitivity check index. Secondary outcomes included glucose and insulin levels during a 75-g oral glucose tolerance test and blood pressure. RESULT(S): Twenty-two women completed the study. Compared with placebo, vitamin D significantly increased 25-hydroxyvitamin D (mean [95% confidence interval] in vitamin D group 20.1 [15.7 to 24.5] ng/mL at baseline and 65.7 [52.3 to 79.2] ng/mL at 12 weeks; placebo 22.5 [18.1 to 26.8] ng/mL at baseline and 23.8 [10.4 to 37.2] ng/mL at 12 weeks). There were no significant differences in quantitative insulin sensitivity check index and other measures of insulin sensitivity; however, we observed trends toward lower 2-hour insulin and lower 2-hour glucose. We also observed a protective effect of vitamin D on blood pressure. CONCLUSION(S): In women with PCOS, insulin sensitivity was unchanged with high-dose vitamin D, but there was a trend toward decreased 2-hour insulin and a protective effect on blood pressure. CLINICAL TRIAL REGISTRATION NUMBER: NCT00907153.
RCT Entities:
OBJECTIVE: To determine the effects of high-dose vitamin D on insulin sensitivity in polycystic ovary syndrome (PCOS). DESIGN: Randomized, placebo-controlled trial. SETTING: Academic medical center. PATIENT(S): Twenty-eight women with PCOS. INTERVENTION(S): Vitamin D3, 12,000 IU, or placebo daily for 12 weeks. MAIN OUTCOME MEASURE(S): The primary outcome was quantitative insulin sensitivity check index. Secondary outcomes included glucose and insulin levels during a 75-g oral glucose tolerance test and blood pressure. RESULT(S): Twenty-two women completed the study. Compared with placebo, vitamin D significantly increased 25-hydroxyvitamin D (mean [95% confidence interval] in vitamin D group 20.1 [15.7 to 24.5] ng/mL at baseline and 65.7 [52.3 to 79.2] ng/mL at 12 weeks; placebo 22.5 [18.1 to 26.8] ng/mL at baseline and 23.8 [10.4 to 37.2] ng/mL at 12 weeks). There were no significant differences in quantitative insulin sensitivity check index and other measures of insulin sensitivity; however, we observed trends toward lower 2-hour insulin and lower 2-hour glucose. We also observed a protective effect of vitamin D on blood pressure. CONCLUSION(S): In women with PCOS, insulin sensitivity was unchanged with high-dose vitamin D, but there was a trend toward decreased 2-hour insulin and a protective effect on blood pressure. CLINICAL TRIAL REGISTRATION NUMBER: NCT00907153.
Authors: Catharina Mattila; Paul Knekt; Satu Männistö; Harri Rissanen; Maarit A Laaksonen; Jukka Montonen; Antti Reunanen Journal: Diabetes Care Date: 2007-07-12 Impact factor: 19.112
Authors: S Hahn; U Haselhorst; S Tan; B Quadbeck; M Schmidt; S Roesler; R Kimmig; K Mann; O E Janssen Journal: Exp Clin Endocrinol Diabetes Date: 2006-11 Impact factor: 2.949
Authors: Anastassios G Pittas; Bess Dawson-Hughes; Tricia Li; Rob M Van Dam; Walter C Willett; Joann E Manson; Frank B Hu Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Y H M Krul-Poel; C Snackey; Y Louwers; P Lips; C B Lambalk; J S E Laven; S Simsek Journal: Eur J Endocrinol Date: 2013-10-23 Impact factor: 6.664
Authors: Jana Figurová; Ingrid Dravecká; Martin Javorský; Jana Petríková; Ivica Lazúrová Journal: Wien Klin Wochenschr Date: 2015-03-19 Impact factor: 1.704
Authors: S Jafari-Sfidvajani; R Ahangari; M Hozoori; H Mozaffari-Khosravi; H Fallahzadeh; A Nadjarzadeh Journal: J Endocrinol Invest Date: 2017-11-06 Impact factor: 4.256
Authors: Lubna Pal; Heping Zhang; Joanne Williams; Nanette F Santoro; Michael P Diamond; William D Schlaff; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan Myers; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2016-05-17 Impact factor: 5.958